Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and performance of vibration-assisted extraction of chronic cardiac implantable electronic device leads: A pre-clinical ovine study.

Heart rhythm·2026
Same author

Clinical and Histopathological Evaluation of Maximal and Supramaximal Energy Direct Selective Laser Trabeculoplasty (DSLT): A Rabbit Model Safety Study.

Lasers in surgery and medicine·2026
Same author

Saroglitazar, a novel PPAR-α/γ agonist, modulates thyroid hormone homeostasis through hepatic UGT expression in wistar rats.

Chemico-biological interactions·2026
Same author

Non-invasive quantification of viability in liver spheroids using deep learning.

Frontiers in bioengineering and biotechnology·2026
Same author

Reduced number of endothelial progenitor cells in adult patients with beta thalassemia major.

Annals of hematology·2026
Same author

Intracranial hemorrhage in patients with primary brain cancer receiving anticoagulation.

Blood vessels, thrombosis & hemostasis·2026

Related Experiment Video

Updated: May 11, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Drug-induced thrombosis: an update.

Yuval Ramot1, Abraham Nyska, Galia Spectre

  • 1Hadassah-Hebrew University Medical Center, P.O. Box 12000, 91120, Jerusalem, Israel. yramot@gmail.com

Drug Safety
|May 4, 2013
PubMed
Summary

Drugs can cause thrombosis through various mechanisms, including endothelial damage and altered blood cell function. Understanding these drug-induced thrombosis pathways is crucial for patient safety and managing thrombotic events.

Area of Science:

  • Pharmacology
  • Hematology
  • Vascular Biology

Background:

  • Drug-induced thrombosis is an increasing concern, potentially causing both venous and arterial thrombotic events.
  • Understanding the mechanisms is vital for safe drug use and managing thrombotic risks.

Purpose of the Study:

  • To review the diverse mechanisms by which drugs can induce thrombosis.
  • To highlight the clinical significance of drug-induced thrombosis.

Main Methods:

  • Literature review of drug-induced thrombosis mechanisms.
  • Analysis of how drugs affect endothelial cells, platelets, and blood cells.
  • Examination of drug effects on coagulation factors and blood viscosity.

Main Results:

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Experiment Videos

Last Updated: May 11, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

  • Drugs can cause direct endothelial damage, promoting platelet adherence and thrombus formation (e.g., contrast media, cytotoxic drugs).
  • Some drugs alter endothelial mediator secretion or directly affect platelets, increasing adhesion and aggregation (e.g., heparin).
  • Drug effects on red and white blood cells, coagulation balance (e.g., oral contraceptives), and blood viscosity (e.g., IVIG) also contribute to thrombosis.

Conclusions:

  • Drug administration is a significant risk factor for thrombosis, often overlooked alongside genetic or cancer-related predispositions.
  • Recognizing drug-induced thrombosis mechanisms aids in safe drug utilization and prompt intervention during thrombotic events.